English
chlorproguanil
Sign in to saveChlorproguanil is an antimalarial drug. In the late 90s and early 2000s, it was studied under collaboration with the UNICEF/UNDP/World Bank Special Program for Research and Training on Tropical Diseases and GlaxoSmithKline. It was a potential alternative to the preexisting combination therapy of chloroquine and sulfadoxine/pyrimethamine, as malaria was showing drug resistance to this approach. It has been trialled in combination therapy with artesunate to treat haemolysis after malaria treatment, however its development was prematurely stopped because of safety concerns secondary to its associ
Research
124 papers- Chlorproguanil-dapsone for treating uncomplicated malaria.The Cochrane database of systematic reviews · 2004
- Chlorproguanil-dapsone for malaria.Lancet (London, England) · 2004
- Chlorproguanil-dapsone for malaria.Lancet (London, England) · 2004
- Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania.Lancet (London, England) · 2001
- Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone.British journal of clinical pharmacology · 2006
via PubMed
~1 min read
Encyclopedic overview
2 sectionsContents
- References
- See also
Chlorproguanil is an antimalarial drug. In the late 90s and early 2000s, it was studied under collaboration with the UNICEF/UNDP/World Bank Special Program for Research and Training on Tropical Diseases and GlaxoSmithKline. It was a potential alternative to the preexisting combination therapy of chloroquine and sulfadoxine/pyrimethamine, as malaria was showing drug resistance to this approach. It has been trialled in combination therapy with artesunate to treat haemolysis after malaria treatment, however its development was prematurely stopped because of safety concerns secondary to its associated risk of haemolytic anaemia in individuals with glucose-6-phosphate dehydrogenase deficiency.
==References==
Excerpted from Wikipedia’s “chlorproguanil” article, available under the CC BY-SA 4.0 licence.